The verdict
Our read at a glance.
Whether a bile acid that helps in cholestatic disease protects a liver being damaged by 17-alpha-alkylated steroids.
- The signal
- The clinical research is genuine and active. TUDCA and its close relative ursodeoxycholic acid have been studied in cholestatic liver disease, and TUDCA specifically has been taken into substantial trials in neurodegeneration, most prominently in amyotrophic lateral sclerosis, based on its effects on endoplasmic reticulum stress and apoptosis. Registered trials continue across hepatic, neurological and metabolic indications. What does not exist is a trial of the use it is most widely taken for: nobody has tested whether it prevents or mitigates hepatotoxicity from anabolic steroids.
- The unknown
- Whether it does anything against the specific injury pattern in question. Steroid-associated liver injury is characteristically cholestatic, which is at least mechanistically adjacent to where bile acids help - but adjacent is not evidence, and taking it may simply mask rising markers rather than prevent damage.
- Our read
- A real compound with a serious research programme attached to indications almost nobody buying it has. The bodybuilding use is a mechanistic guess that has never been tested, and its most likely practical effect is to make people comfortable running orals for longer.
The mechanism
How it works.
TUDCA is the taurine conjugate of ursodeoxycholic acid, a hydrophilic bile acid. Bile acids exist on a spectrum from hydrophobic to hydrophilic, and the hydrophobic ones are detergent-like and damaging to hepatocyte membranes when they accumulate, as happens in cholestasis. Adding a hydrophilic bile acid shifts the composition of the circulating pool toward the less toxic end and promotes bile flow, which is the basis of its use in cholestatic disease. Separately, and this is what drives the neurology work, TUDCA acts as a chemical chaperone that reduces endoplasmic reticulum stress and inhibits apoptosis, effects demonstrated in cell and animal models of neurodegeneration. The bodybuilding rationale borrows the first mechanism: 17-alpha-alkylated steroids cause a cholestatic pattern of injury, so a drug that improves bile flow ought to help. That reasoning is coherent and it has never been tested against that exposure.
Safety & regulatory boundary
The consequential part.
Not an approved drug in the United States, though the related ursodeoxycholic acid is approved for specific hepatobiliary indications. Sold as a supplement, so identity and potency depend on the manufacturer. Generally well tolerated, with diarrhoea the common effect. The real hazard is behavioural rather than toxicological: believing a liver is protected can extend exposure to the thing damaging it.
What's next
What we're watching.
The neurodegeneration trial programme, and any study that actually tests the hepatoprotective claim in this population.
Context
Why this is discussed.
It is the near-universal recommendation for liver support during oral steroid use, and it is treated in that world as established rather than assumed.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2026-10-01
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-06
ClinicalTrials.gov · PHASE2 · TERMINATED · 2023-01-09
ClinicalTrials.gov · PHASE2/PHASE3 · COMPLETED · 2023-12-21
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-01-19
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2023-03-03
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2026-04-02
ClinicalTrials.gov · COMPLETED · 2018-02-01
Indexed literature (PubMed)12
Wang H et al. · J Agric Food Chem · 2024
Khalaf K et al. · Transl Neurodegener · 2022
Yu S et al. · Kidney Int · 2024
Ketabforoush A et al. · Clin Drug Investig · 2024
Pike CM et al. · Infect Immun · 2022
Xu J et al. · Int Immunopharmacol · 2025
Li J et al. · Curr Neuropharmacol · 2024
Liu JY et al. · Sci China Life Sci · 2025
Lee CH et al. · Neurosci Lett · 2020
Vavrušáková B et al. · Klin Onkol · 2025
Cao M et al. · Biochem Pharmacol · 2025
Keep reading